Novo Nordisk's Balancing Act: Record Pill Prescriptions vs. Relentless Price Erosion

Wegovy oral GLP-1 reached 3M US scripts in 5 months, but pricing pressure, competition from Lilly and generics, and technical weakness challenge Novo’s growth outlook.

Three million prescriptions in five months. That is the tally for Novo Nordisk’s Wegovy pill since its US launch, and more than 80% of those scripts have gone to patients who had never tried a GLP-1 drug before. The oral formulation is expanding the market rather than cannibalising the injectable business — the first million came in 12 weeks, the second in just ten. Yet the stock, after a 9.5% weekly surge to €41.59, is barely clinging to its 200-day moving average at €41.05. That precarious perch captures the central dilemma: can volume growth outrun a structural price collapse?

The UK’s MHRA has now cleared the Wegovy pill for the European market, and a logistics tie-up with Amazon promises same-day delivery that could turbocharge patient access. Novo also sits on a pipeline card in CagriSema, a GLP-1/amylin combination that filed for FDA approval in December 2025. In the REDEFINE-1 study, CagriSema delivered a 22.7% mean weight loss at 68 weeks, with over 40% of participants losing at least a quarter of their body weight. Additional data from the REIMAGINE-2 programme, presented at the ADA congress in June 2026, showed superior HbA1c reductions in type 2 diabetes versus semaglutide alone. But the company’s own 2026 guidance anticipates a revenue decline of 4% to 12% in constant currencies, driven by the US Most-Favoured-Nations agreement and exclusivity losses on semaglutide in several markets.

The bearish counterweight is substantial. Adjusted for a one-off accounting effect, first-quarter 2026 revenues shrank 4% in constant currency. US rebates on gross sales hit 70% in 2025, and the adjusted gross margin slid from 83.5% to 80.6%. The Wegovy pill’s volume has not yet compensated for that margin bleed. Meanwhile, Eli Lilly’s Foundayo entered the oral GLP-1 fray in April 2026, and in the head-to-head REDEFINE 4 trial, CagriSema failed to beat Lilly’s Zepbound on the primary endpoint after 84 weeks — a blow to Novo’s planned growth pillar.

Competition is also arriving from smaller players. Viking Therapeutics reported strong phase 2 data for its candidate VK2735, with 14.7% weight loss via injection and 12.2% with an oral formulation. And structural threats loom beyond the clinic: semaglutide generics are already on the market in India, approved in Canada, and expected soon in China, where Novo’s adjusted revenues slumped 10% after list-price cuts in late 2025. In South Africa, Novo won a court injunction to block local copies, but Russia has authorised domestic production until 2027. A less visible risk comes from the University of Adelaide, which warned that the absorption enhancer SNAC in oral semaglutide may raise inflammation markers and liver weight — a potential regulatory headache down the line.

Technical indicators add near-term caution. The relative strength index stands at 69.2, close to overbought territory, and the 200-day line has acted as resistance during previous recovery attempts. The stock remains 32% below its 52-week high of €61.20, and a pullback towards the 50-day moving average at €37.33 is not out of the question. Yet the buyback programme provides a floor: Novo has been repurchasing shares since February, acquiring roughly 21 million B-shares as part of a programme worth up to 15 billion Danish kroner, alongside a separate new programme of 11.2 billion kroner.

The next hard test comes on 5 August 2026 with the second-quarter results. The critical metric is not initial prescriptions but retention — how many patients stay on the pill through the titration process. That will determine whether the headline script numbers translate into durable per-patient revenue. If volume momentum holds and the European rollout, planned for the second half of 2026, starts to chip in, Novo could beat the lower end of its own guidance. An FDA decision on CagriSema in the fourth quarter would then act as a revaluation catalyst, especially if it becomes the first GLP-1/amylin combination to market.

If the Q2 report instead shows US price erosion accelerating faster than pill volumes can compensate, or if international launches stumble, the recovery will likely end at the 200-day line. Below that, the path reopens towards the year’s low of €30.25. Optimists counter that the stock trades at an expected EV/EBITDA of 10.2, less than half Eli Lilly’s multiple of 22, implying the market has already priced in significant pessimism. For Novo Nordisk, the coming months will decide whether that discount represents a buying opportunity or a value trap.